Results 51 to 60 of about 210,137 (310)

Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up [PDF]

, 2017
BACKGROUND: Reorganisation of clinical follow-up care in England was proposed by the National Cancer Survivorship Initiative (NCSI), based on cancer type and treatment, ranging from Level 1 (supported self-management) to Level 3 (consultant-led care ...
Lancashire, Emma R, Levitt, Gill A, Frobisher, Clare, Oeffinger, Kevin C., Guha, J, Joyeeta Guha, Levitt, Gill A., Gill A Levitt, David L Winter, Emma R Lancashire, Winter, David L, Kevin C Oeffinger, Raoul C Reulen, Guha, Joyeeta, Glaser, A, Glaser, Adam, Reulen, Raoul C; id_orcid, Clare Frobisher, Cutter, David J., Hawkins, MM, Adam Glaser, Lancashire, Emma R., Winter, DL, Kelly, Julie, Michael M Hawkins, Oeffinger, Kevin C, Winter, David L., Hawkins, M, Reulen, RC, null null, Levitt, GA, Oeffinger, KC, Kelly, J, Reulen, Raoul C, Frobisher, Clare; id_orcid, Cutter, David J, Cutter, DJ, David J Cutter, Frobisher, C, Lancashire, ER, Julie Kelly   +40 more
core   +1 more source

Deep Sequencing of FLT3‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm, Bea Tornberg, Erik Delsing Malmberg, Henrik Hasle, Kristian Løvvik Juul‐Dam, Lars Palmqvist, Borhan R. Saeed, Giti Shah Barkhordar, Anastasia Soboli, Anna Staffas, Jonas Abrahamsson, Linda Fogelstrand   +11 more
wiley   +1 more source

Patient involvement in the development of childhood, adolescent and young adult cancer survivorship guidelines: recommendations from EU-CAYAS-NET ambassadors

Research Involvement and Engagement
Background Survivors of Childhood, Adolescent, and Young Adult (CAYA) cancer can face long-term health complications due to adverse effects of cancer and its treatment, necessitating lifelong follow-up care.
Jikke Wams, Jaap den Hartogh, Hannah Gsell, Carina Schneider, Barbara Brunmair, Anna Zettl, Zuzana Tomášiková, Anita Kienesberger, Katie Rizvi, Ana M. Totovina, Roderick Skinner, Jeroen te Dorsthorst, Helena J. H. van der Pal, Leontien C. M. Kremer, Elvira C. van Dalen, Renée L. Mulder, the EU-CAYAS-NET ambassadors and consortium   +16 more
doaj   +1 more source

Benefits of Exercise Training for Children and Adolescents Undergoing Cancer Treatment: Results From the Randomized Controlled MUCKI Trial

Frontiers in Pediatrics, 2020
Objective: In cancer patients, the impairment in muscle function is a frequently observed phenomenon. However, comprehensive evaluation of the effect of exercise training on muscle function in childhood cancer patients (CCPs) is sparse and therefore ...
Sandra Stössel, Marie A. Neu, Arthur Wingerter, Wilhelm Bloch, Philipp Zimmer, Claudia Paret, Khalifa El Malki, Freerk T. Baumann, Alexandra Russo, Nicole Henninger, Nadine Lehmann, Henrike Otto, Jörg Faber   +12 more
doaj   +1 more source

Claudin‐6 Protein Expression in Atypical Teratoid/Rhabdoid Tumors Is Strongly Enriched in the Molecular Subgroup AT/RT‐TYR

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke, Christian Thomas, Michael C. Frühwald, Pascal D. Johann, Martin Hasselblatt   +4 more
wiley   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray

STAR Protocols, 2023
Summary: Here, we present a protocol for deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray.
James P.R. Hacking, Dean Thompson, Edward C. Schwalbe, Steven C. Clifford, Daniel Williamson   +4 more
doaj   +1 more source

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási, Bernadett Borbála Huszti, Gábor Barna, Marko Kavcic, Janez Jazbec, Lennart Lenk, Vera Münch, Sophia Polychronopoulou, Ágnes Márk, Maria Thastrup, Lüder H. Meyer, Kjeld Schmiegelow, Cornelia Eckert, Christina Halsey, Dániel J. Erdélyi   +14 more
wiley   +1 more source

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma

Journal for ImmunoTherapy of Cancer, 2020
Background Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis.
Shannon A Kreuser, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Richard G Ellenbogen, Courtney A Crane, Jennifer L Gardell, Brooke Prieskorn, Stephanie Balcaitis, Amira Davis   +9 more
doaj   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source